Won Gon Kim

Won Gon Kim


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BKBomin Kim
Bomin Kim
JPJi-Su Park
Ji-Su Park
HCHa-Young Choi
Ha-Young Choi
SYSang Sun Yoon
Sang Sun Yoon
WKWon Gon Kim
Won Gon Kim
To address the drug-resistance of bacterial pathogens without imposing a selective survival pressure, virulence and biofilms are highly attractive targets. Here, we show that terrein, which was isolated from Aspergillus terreus, reduced virulence factors (elastase, pyocyanin, and rhamnolipid) and biofilm formation via antagonizing quorum sensing (QS) receptors without affecting Pseudomonas aeruginosa cell growth. Additionally, the effects of terrein on the production of QS signaling molecules and expression of QS-related genes were verified. Interestingly, terrein also reduced intracellular 3,5-cyclic diguanylic acid (c-di-GMP) levels by decreasing the activity of a diguanylate cyclase (DGC). Importantly, the inhibition of c-di-GMP levels by terrein was reversed by exogenous QS ligands, suggesting a regulation of c-di-GMP levels by QS; this regulation was confirmed using P. aeruginosa QS mutants. This is the first report to demonstrate a connection between QS signaling and c-di-GMP metabolism in P. aeruginosa, and terrein was identified as the first dual inhibitor of QS and c-di-GMP signaling.

6 September 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
YKYu Jin Kim
Yu Jin Kim
HKHyun-Ju Kim
Hyun-Ju Kim
GKGeon-Woo Kim
Geon-Woo Kim
KCKyungyun Cho
Kyungyun Cho
STShunya Takahashi
Shunya Takahashi
WKWon Gon Kim
Won Gon Kim

28 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CZChang Ji Zheng
Chang Ji Zheng
MSMi-Jin Sohn
Mi-Jin Sohn
SLSangku Lee
Sangku Lee
WKWon Gon Kim
Won Gon Kim
Bacterial enoyl-acyl carrier protein reductase (FabI) is a promising novel antibacterial target. We isolated a new class of FabI inhibitor from Penicillium chrysogenum, which produces various antibiotics, the mechanisms of some of them are unknown. The isolated FabI inhibitor was determined to be meleagrin by mass spectroscopy and nuclear magnetic resonance spectral analyses, and its more active and inactive derivatives were chemically prepared. Consistent with their selective inhibition of Staphylococcus aureus FabI, meleagrin and its more active derivatives directly bound to S. aureus FabI in a fluorescence quenching assay, inhibited intracellular fatty acid biosynthesis and growth of S. aureus, and increased the minimum inhibitory concentration for fabI-overexpressing S. aureus. The compounds that were not effective against the FabK isoform, however, inhibited the growth of Streptococcus pneumoniae that contained only the FabK isoform. Additionally no resistant mutant to the compounds was obtained. Importantly, fabK-overexpressing Escherichia coli was not resistant to these compounds, but was resistant to triclosan. These results demonstrate that the compounds inhibited another target in addition to FabI. Thus, meleagrin is a new class of FabI inhibitor with at least one additional mode of action that could have potential for treating multidrug-resistant bacteria.

1 November 2008 in The Journal of Antibiotics
Verified
Journal Article
Closed access
MSMi-Jin Sohn
Mi-Jin Sohn
CZChang-Ji Zheng
Chang-Ji Zheng
WKWon Gon Kim
Won Gon Kim

1 January 2012 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
YKYu Jin Kim
Yu Jin Kim
MSMi-Jin Sohn
Mi-Jin Sohn
WKWon Gon Kim
Won Gon Kim
Bacterial enoyl-acyl carrier protein (ACP) reductase has been confirmed as a novel target for antibacterial drug development. In the screening of inhibitors of Staphylococcus aureus enoyl-ACP reductase (FabI), we found that a methanol extract of leaves of Morus alba L. potently inhibited S. aureus FabI as well as growth of S. aureus. The active principles were identified as chalcomoracin and moracin C by MS and NMR analysis. Chalcomoracin and moracin C inhibited S. aureus FabI with IC50 of 5.5 and 83.8 µM, respectively. They also prevented the growth of S. aureus with minimum inhibitory concentration (MIC) of 4 and 32 µg/mL, respectively. Consistent with their inhibition against FabI and bacterial growth, they prevented [14C]acetate incorporation into fatty acid in S. aureus while didn’t affect protein synthesis. In this study, we reported that chalcomoracin and moracin C, potent antibacterial compounds from Morus alba, inhibited FabI and fatty acid synthesis.

26 May 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
BHBaek-Soo Han
Baek-Soo Han
KKKyoung-Shim Kim
Kyoung-Shim Kim
YKYu Jin Kim
Yu Jin Kim
HJHoe-Yune Jung
Hoe-Yune Jung
YKYoung-Mi Kang
Young-Mi Kang
WKWon Gon Kim
Won Gon Kim